RPAY Jumps As Forager Launches $4.80 Cash Takeover Bid

Repay Holdings Corporation stocks have been trading up by 27.68 percent, driven primarily by strong earnings and upgraded guidance.

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading RPAY

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

What Traders Need To Know

Forager Capital, owning about 13% of Repay Holdings Corporation, has proposed buying the rest of the company for $4.80 per share in cash, a 75% premium to the recent 30‑day VWAP of $2.75.
The board of Repay Holdings Corporation has hired J.P. Morgan and legal counsel to review Forager’s unsolicited, non-binding offer and is asking shareholders to sit tight while it weighs this bid against its existing KUBRA strategy.
A limited‑duration stockholder rights plan now caps effective control above 12.5%, aiming to block any creeping takeover without a proper premium, while still allowing a vote on fully financed, all-cash qualifying offers.
Activist Veradace Partners, holding 8.4%, is pushing to kill the KUBRA Data Transfer deal and add shareholder directors, citing governance concerns and RPAY’s sharp drop and weak trading after that acquisition was announced.
Management at Repay Holdings Corporation is standing by the KUBRA acquisition, arguing it boosts bill-pay scale and recurring, non-discretionary payment flows, even as shareholder pressure and takeover interest turn RPAY into an event-driven battleground.

Weekly Update Apr 13 – Apr 17, 2026: On Saturday, April 18, 2026 Repay Holdings Corporation stock [NASDAQ: RPAY] is trending up by 27.68%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Finance industry expert:

Analyst sentiment – positive

Repay Holdings operates a subscale, challenged niche in integrated payments and bill-pay, with FY revenue of ~$309M growing mid-teens over five years but with deeply negative profitability (EBIT margin -85%, EBITDA margin -52%, ROE -41%). The business is currently driven by non-cash impairment (Q4 asset impairment ~$139M) and restructuring rather than core growth. Positively, free cash flow is solid (~$13.8M in Q4, P/FCF ~3.7x) and the balance sheet is manageable (D/E ~0.9x, current ratio 0.8x, EV/Sales ~0.88x, P/B ~0.56x), suggesting distressed but not broken fundamentals.

Technically, RPAY has transitioned from a stagnant micro-cap pattern (3.07–3.18 range) to a news-driven breakout, with price spiking to a 4.31 intraday high and closing at ~4.06 on elevated volume after the $4.80 bid. The dominant trend is now short-term bullish with a clear event-driven overhang. Immediate actionable level: $4.00 is key near-term support; above that, the $4.60–4.80 zone is the upside target and likely supply area, where risk-reward favors trimming or selling into strength.

More Breaking News

Near-term performance is dominated by the Forager $4.80 all-cash proposal and the board’s poison pill, set against activist opposition to the KUBRA deal. Relative to diversified financials, RPAY screens optically cheap on EV/Sales and P/B but justifiably so given persistent losses and governance friction. Base case: a transaction or revised strategic path anchors value around $4.50–$5.00, with downside support near $3.25 if a deal collapses. Tactically, risk-tolerant investors can own toward $4 with a $3.25 stop and $4.80 target.

Quick Financial Overview

Repay Holdings Corporation is now trading as a classic event-driven name, with price action anchored to the $4.80 per-share cash proposal from Forager Capital. The weekly data show a quiet base around $3.07–$3.18 before a sharp gap to a $4.31 high on 2026/04/17, closing near $4.06. That gap-up of roughly 30% in a single session lines up with the news that shares were up about 35% in premarket trading once the takeover proposal hit the tape.

Intraday, the 5‑minute candle around the move shows a wide range from roughly $3.73 to $4.29, with a close near the high end. This tells traders two things: first, there was strong demand above prior prices; second, there was real volatility and intraday shakeout as shorts covered and fast money repositioned. From here, the deal price effectively becomes a reference level and soft ceiling until there is either a sweetened bid, a rival bidder, or a breakdown in talks.

Under the surface, RPAY’s fundamentals show a complex picture. Revenue is about $309.3M with a strong 75% gross margin, but profitability metrics are deeply negative, with EBIT margin around -85% and profit margins also heavily in the red. Cash flow, however, looks better than earnings: trailing free cash flow is about $13.8M for the latest reported quarter, and valuation ratios show a low price-to-sales near 0.88 and price-to-book near 0.56. Leverage is moderate, with total debt-to-equity around 0.9 and a current ratio of 0.8, so the balance sheet is not risk-free but not extreme either, which matters if the takeout fails and the stock trades back on fundamentals.

Conclusion

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.

Start Your Trial Now!